Regulators urged to approve game-changing Alzheimer's drug donanemab

Regulators urged to approve game-changing new Alzheimer’s drug that slows decline by up to 60% amid hope donanemab could be on the NHS in two years Experts say Brits with condition deserve not to left in limbo over the treatment READ MORE: Incredible transformation of Alzheimer’s patient on new drug Britain’s regulators are being urged to rapidly approve new Alzheimer’s […]
» Read more